Having trouble accessing articles? Reset your cache.

Coronavirus Analysis

In response to the urgent need for information about the coronavirus crisis, we are providing this collection of BioCentury analysis of the coronavirus outbreak. The analysis in this collection is free and will be updated frequently by our team as research develops. Please send suggestions for additional coverage to: ncov2019@biocentury.com. We are developing stories about the discovery, testing and deployment of medical countermeasures, and the response of the biomedical community to the outbreak.

BC_Coronavirus_012720_BannerImage_i.jpg

Gilead CEO Daniel O’Day said a patent application from two Chinese institutions for the use of the company’s unapproved antiviral remdesivir to treat the coronavirus “has no impact on what we’re going to do for global health”

Feb 5, 2020 | 5:35 PM PST

Regeneron and BenevolentAI unveiled a deal and a platform, respectively, on Tuesday that could yield therapies against 2019-nCoV that go beyond anti-inflammatory drugs for other viral infections

Feb 4, 2020 | 5:39 PM PST

Almost all major biopharma MNCs are conducting clinical trials in China that could face disruptions as the outbreak of 2019-nCoV acute respiratory disease continues to unfold

Feb 4, 2020 | 5:48 PM PST

FDA and EMA each unveiled measures Tuesday to combat the 2019-nCoV outbreak, with the U.S. agency issuing emergency use authorization for a diagnostic and its European counterpart activating its emerging health threats management plan

Feb 4, 2020 | 5:48 PM PST

Gilead’s remdesivir is the most promising candidate for treating 2019-nCoV acute respiratory disease, according to a draft report of WHO’s R&D Blueprint Clinical Trials expert group

Feb 4, 2020 | 4:56 PM PST

As China responds to the 2019-nCoV virus outbreak, executives of Chinese life sciences companies have pointed out that efforts to fight the virus could affect clinical trials across the nation, including postponement of new trials and continued enrollment of ongoing trials and increased usage of remote monitoring

Feb 4, 2020 | 12:53 PM PST

Nine clinical trials are under way to test therapeutic interventions for 2019-nCoV acute respiratory disease, according to ClinicalTrials.Gov and the Chinese Clinical Trial Register

Feb 3, 2020 | 5:34 PM PST

As Gilead plans a Chinese trial of remdesivir to treat the coronavirus, health authorities in Washington state reported that compassionate use of the nucleotide analog prodrug resolved almost all disease symptoms in one infected patient

Feb 3, 2020 | 5:03 PM PST

GlaxoSmithKline will provide its AS03 adjuvant technology to enhance 2019-nCoV vaccines that are being funded by the Coalition for Epidemic Preparedness Innovations, GSK and CEPI announced Sunday

Feb 2, 2020 | 8:41 PM PST

A tally of ongoing clinical trials in Wuhan, the city at the center of the coronavirus outbreak

Jan 31, 2020 | 5:56 PM PST

HHS Secretary Alex Azar Friday declared that 2019 Novel Coronavirus (2019-nCoV) poses a public health emergency

Jan 31, 2020 | 3:10 PM PST

Industry and academic centers are rushing to create new vaccines and therapeutics targeting coronavirus

Jan 30, 2020 | 5:22 PM PST

Ascletis is seeking the approval of China’s NMPA for emergency use of its protease inhibitors to treat 2019-nCoV coronavirus after the government released guidelines suggesting AbbVie’s Kaletra as a treatment for the virus

Jan 29, 2020 | 6:04 PM PST

AbCellera Biologics Inc. has started a program to discover mAbs as potential treatments for patients infected with the 2019-nCoV that was first identified in Wuhan, China, the company’s CEO, Carl Hansen, told BioCentury

Jan 28, 2020 | 1:37 PM PST

Two more companies have announced that they are developing vaccines to protect against the 2019-nCoV outbreak that was first detected in Wuhan, China, bringing the total number of vaccine development programs to at least 10

Jan 27, 2020 | 3:20 PM PST

The coronavirus outbreak is creating a testbed for new vaccine and therapeutic technologies

Jan 24, 2020 | 8:02 PM PST

The rapid sharing of the genetic sequence of the 2019 novel coronavirus (2019-nCoV), first identified in Wuhan, China, has sparked an extraordinary response from biopharma companies, academic researchers and governments

Jan 23, 2020 | 2:04 PM PST

At least four groups have started to develop vaccines to protect against the 2019 Novel Coronavirus (2019-nCoV) that was first detected in Wuhan, China

Jan 21, 2020 | 5:02 PM PST